特一药业集团股份有限公司关于第六届董事会第二次会议决议的公告

Group 1 - The company held its sixth board meeting on August 15, 2025, where all six attending directors approved the resolutions [2][3][4] - The board approved the use of idle funds from a specific stock issuance to temporarily supplement working capital and for cash management [3][4][17] Group 2 - The company raised a total of approximately 275 million yuan from the issuance of 20,146,514 shares at a price of 13.65 yuan per share, with a net amount of about 268.89 million yuan after deducting issuance costs [7][18] - As of June 30, 2025, the company had utilized 60 million yuan of the raised funds, leaving a balance of approximately 21.05 million yuan [8][20] - The company plans to use up to 100 million yuan, which is 37.19% of the net raised funds, to temporarily supplement working capital for a period not exceeding 12 months [11][12] Group 3 - The company intends to use up to 90 million yuan of idle funds for cash management, focusing on safe and liquid investment products [17][22] - The cash management will not affect the normal operation of the fundraising projects and is expected to enhance the efficiency of fund usage [30][31]